Interactions of calmodulin antagonists with calcium antagonists binding sites.
Calmodulin antagonists have calcium entry blocking properties. In order to quantitatively investigate the interactions of these drugs with calcium channels, their effect on [3H]nitrendipine and [3H]d-cis-diltiazem binding to rat cerebral cortex membrane preparations was compared to their inhibitory effect on the activation of cyclic nucleotide phosphodiesterase by calmodulin. The potency of most antagonists to inhibit [3H]nitrendipine binding was correlated with their calmodulin inhibitory potency. However, bepridil (K0.5 = 280 nM), chlorpromazine (K0.5 = 3 microM), triflupromazine (K0.5 = 1.5 microM), imipramine (K0.5 = 3 microM) and propranolol (K0.5 = 14 microM) were much more active on [3H]d-cis-diltiazem binding than on either [3H]nitrendipine binding or calmodulin, suggesting that these compounds bind to higher affinity sites on the calcium antagonist target protein. Moreover, the potencies of these compounds to compete with [3H]d-cis-diltiazem and to inhibit calcium-induced contractions in depolarized smooth muscle were correlated (R = 0.76, p less than 0.02). These data suggest that low concentrations of these hydrophobic drugs which have calcium and calmodulin antagonistic properties inhibit smooth muscle contraction through calcium entry blockade, not calmodulin antagonism.
Schaeffer
P
P
Laboratoire de Pharmacologie Cellulaire et Moléculaire, CNRS URA 600, Faculté de Pharmacie, Université Louis Pasteur de Strasbourg, Illkirch, France.
Lugnier
C
C
Stoclet
J C
JC
D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects; D001665:Binding Sites; D002118:Calcium / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000378:metabolism; D015220:Calcium Channels / Q000187:drug effects*; D002147:Calmodulin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D004110:Diltiazem / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D007700:Kinetics; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009568:Nitrendipine / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D014316:Tritium
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D002147:Calmodulin; D014316:Tritium; D009568:Nitrendipine; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases; D004110:Diltiazem; D002118:Calcium